


# PNEU-C20 Eligibility for Populations at Increased Risk of Invasive Pneumococcal Disease (IPD)

AHS 2025 Standard # 07.293 (April 2025)

For individuals using immunosuppressive therapy including:

- Long-term use of corticosteroids;
- Biologic and non-biologic immunosuppressive therapies for inflammatory arthropathies (e.g. systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile arthritis)

**Note:** Individuals 18 years of age and older who have received one dose of Pneu-C20 are considered complete, and do not need to be assessed through the algorithm.



**IMPORTANT:** Pneu-C20 should be given at least **one year** after a Pneumo-P dose, to be optimally effective.